SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending downwards as the rise of prediction markets, particularly Polymarket and Kalshi, sparks concerns about increased competition and potential loss of market share; Amazon is also teaming up with FanDuel for real-time betting updates during NBA games. The community is debating whether DraftKings is failing to innovate and adapt to this changing landscape, especially with Donald Trump Jr’s investment into Polymarket. Some investors express frustration with the stock's performance, citing missed opportunities and a lack of positive catalysts.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending amid discussions of a potential $70 billion investment and a possible drug-pricing deal with the White House, sparking debate about the implications of government involvement and pricing strategies. The community is analyzing the potential impact of these developments on Pfizer's future and comparing it to competitors in the pharmaceutical sector. Some are also looking at poor obesity data from a company $PFE recently bought.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is trending due to a mixed sentiment, with some traders attributing recent price drops to a $14.2 billion AI cloud infrastructure deal with CoreWeave, while others point to broader market factors or concerns about Meta's spending.  The community is actively discussing potential bounce opportunities and whether the stock is currently oversold, while also reacting to news of Instagram reaching 3 billion monthly active users. Discussions also include Meta possibly tapping Google's Gemini AI for ad targeting.

Draganfly, Inc. engages in the manufacture and sale of commercial unmanned aerial vehicle systems and software serving the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. Its products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and software used for tracking, live streaming, and data collection. The firm also offers custom engineering, training, simulation consulting, as well as data and flight training services. The company was founded by Zenon Dragan and Christine Dragan in 1998 and is headquartered in Saskatoon, Canada.

Draganfly Inc

Draganfly ($DPRO) is trending after the U.S. Army selected the company to supply its Flex FPV drone systems, including on-site manufacturing and training. The community is discussing the potential for a gamma squeeze and government support, with some highlighting the company's low float and high short interest. Bullish sentiment is fueled by expectations of future contracts and the increasing demand for military drones.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed's stock is trending following its emergence from Chapter 11 bankruptcy, marked by a financial restructuring that significantly reduced debt. The community is actively discussing the implications of the restructuring, particularly the conversion of old shares to new ones and the potential for a short squeeze. Some investors express concerns about dilution, while others see opportunity in the company's improved financial health and position in the silicon carbide market.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending due to a reported $14 billion AI cloud deal with Meta, sparking excitement about the company's growth potential and role in the AI infrastructure space. The community is discussing potential revenue boosts, S&P 500 inclusion, and the implications for key hardware suppliers like Supermicro. Bullish sentiment is high, with many viewing CoreWeave as a major player in the rapidly expanding AI sector alongside Nvidia.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending due to recent partnerships with major tech companies like NVIDIA and OpenAI, sparking excitement around its potential in agentic AI. The community is discussing a possible short squeeze, given the stock's high short interest, while also considering the impact of ongoing insider sales and comparing $PATH to competitors. Overall, the partnerships have many bullish, while others are not as convinced this is a long-term revenue driver.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SOFI is experiencing a pullback after a period of gains, leading to a divided community as some investors buy the dip while others express frustration. The conversation centers on the potential for a continued downtrend versus a recovery, with upcoming catalysts like crypto integration and earnings announcements as key factors. Some traders are also looking at SOFI compared to competitors like HOOD.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as it approaches new all-time highs, fueled by analyst upgrades and optimism surrounding AI infrastructure and partnerships, including potential benefits from increased AI spending by Big Tech. Community members are actively discussing potential price targets, breakout levels, and the impact of these developments on the broader market, while considering factors like options flow and potential pullbacks. The stock's momentum is also being weighed against concerns about market conditions and the broader tech sector's reliance on a few key players.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a significant stock drop triggered by a now-retracted LinkedIn post from an FDA official questioning the clinical benefit and safety of Aurinia's drug, Lupkynis. The community is expressing outrage, demanding accountability, and discussing potential lawsuits against the official for market manipulation, with some speculating about past conflicts and short-selling conspiracies. Despite the company's defense of the drug and its FDA approval, uncertainty prevails, and shareholders are closely watching for further developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cigna to Support Cleerly's AI Cardiovascular Imaging Solutions

CI expands coverage to Cleerly's AI cardiovascular imaging, boosting access, early detection and digital healthcare adoption.

Humana Extends TailorCare Tie-Up to Enhance MA Member Health

HUM expands its TailorCare partnership to Dallas and Denver, aiming to boost MA member health and cut MSK-related costs.

Zacks Industry Outlook Highlights Cigna and Humana

Cigna and Humana stand out in the HMO space, leveraging growth platforms and Medicare demand despite cost and regulatory pressures.

2 HMO Stocks Poised to Thrive Despite Escalating Medical Costs

The Medical-HMO industry benefits from strength in commercial plans, M&A and expected Medicare rate hikes, but rising costs, regulatory shifts and workforce shortages strain margins. CI and HUM are likely to navigate industry storms.

Will UnitedHealth's Push for Access to Trump Calm Investor Jitters?

UNH doubles lobbying spend, reshapes legal team and seeks Trump access amid regulatory risks.

Bank of America (BofA) raised its price target on Humana to $330 from $312 on Tuesday, pointing to improved sentiment in the managed care sector following UnitedHealth’s preliminary Medicare Advantage Star Ratings update.&nbsp;The bank’s research arm&nbsp;maintained a ‘Neutral’ rating on Humana shares,&nbsp;which rose on Wednesday following the worst one-day drop in over a year in the previous session after reports suggested that the cut points for the 2026 Medicare Advantage Stars Ratings, due for official release in October, will be more stringent.Analyst Kevin Fischbeck said UnitedHealth’s stronger-than-expected ratings data prompted BofA to assign a higher peer multiple to Humana. However, he cautioned that uncertainty over 2027 Medicare Advantage rates could delay the company’s earnings recovery.Meanwhile, analysts at Raymond James said the latest news about ratings "potentially pours cold water" on hopes that Humana could win back some of its lost ratings in 2026, a year earlier than management had guided. The research firm stated that the stock "was getting a little ahead of itself" following its surge from the year's nadir in July. Still, Raymond James sees the pullback as a buying opportunity, reaffirming its 'Outperform' rating and arguing that Humana's implied 2028 valuation now stands at just 6.7 times its earnings per share.&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/united-health-fuels-bullish-mood-with-4-month-high-close-as-medicare-star-ratings-reaffirmed-2025-outlook-ease-investor-fears/chwjCVnRdM9">UnitedHealth said about 78% of its members</a> are expected to be in plans rated four stars or higher for Star Year 2026, an improvement from last year and in line with historical averages.&nbsp;The insurer reaffirmed its 2025 adjusted earnings outlook of at least $16 per share, on revenue between $445.5 billion and $448 billion, including its recent&nbsp;acquisition of Amedisys.Wall Street analysts said the update was “better than feared,” even as tougher Consumer Assessment of Healthcare Providers and Systems (CAHPS) cut points raised the bar.&nbsp;Truist raised its target on UnitedHealth to $365 from $310 with a ‘Buy’ rating, while JPMorgan and Barclays reiterated ‘Overweight’ calls, saying the disclosure should ease investor concerns. Leerink, which kept an ‘Outperform’ rating, said the performance was notable given that 58% of 2026 measures were tougher.The preliminary disclosure, covering Star Year 2026 and Payment Year 2027, is a key driver of future Medicare Advantage reimbursements.&nbsp;On Stocktwits, retail sentiment was 'extremely bullish' for Humana amid 'extremely high' message volume, while it was 'bullish' for UnitedHealth with 'high' volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/HUM">Humana’s stock</a> has risen 8.6%, while&nbsp;<a href="https://stocktwits.com/symbol/UNH">UnitedHealth’s stock</a>&nbsp;has declined 30.7% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The MyHumana app page is displayed on a smartphone in the Apple App Store in front of the Humana Inc logo on October 30, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Humana Stock In Focus: BofA Raises Price Target After UnitedHealth Stars Data, Raymond James Sees Buying Opportunity

The brokerage lifted its price target on Humana to $330 but kept a ‘Neutral’ rating, citing lingering uncertainty over 2027 Medicare Advantage rates.

Equity

Humana Wins TVH Assets in Bankruptcy Sale, But Cut Points Drag Shares

HUM scoops up $68M Florida care centers, but star rating hurdles send shares tumbling 12%. Can HUM turn risk into reward?

UnitedHealth Finds Its Stars, Soars 8.6% as Humana Trips on Cut Points

UNH surges 8.6% as it projects stable Medicare Advantage star ratings, easing investor worries over performance.

Humana (HUM) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

UnitedHealth & AI: Can Technology Redefine Healthcare Efficiency?

UNH is leveraging AI to streamline insurance and care delivery, aiming to boost efficiency and improve patient outcomes.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$258.34
Prev Close	$255.23
Open	$255.38
Dividend Yield	1.40%
50-Day Moving Average	$270.80
Beta	0.31
Avg. Volume	1.39M
PE Ratio	19.59

52-Week High	$315.40
52-Week Low	$206.87
Market Capitalization	$30.7B
EPS (Annual)	$9.99
Price to Book	1.68
Revenue Per Employee	$1.79M
Enterprise Value/EBITDA	N/A

HUM
Humana Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HUM News

HUM Humana Inc